--- title: "Lifecore Biomedical (LFCR) news: class action and settlement" url: "https://aibio.space/companies/lifecore-biomedical/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "LFCR class action and settlement news: Lifecore reports July hearing on securities class action settlement. Lifecore Biomedical, Inc." --- LFCR Lifecore Biomedical, Inc. NASDAQ · United States # Lifecore Biomedical (LFCR) news LFCR class action and settlement news Legal · 2026-10-20 ## [Lifecore reports July hearing on securities class action settlement](https://aibio.space/news/lifecore-reports-july-hearing-securities-class-action-settlement/) Carew v. Lifecore Biomedical names the company and unnamed executive officers. The final approval hearing was held on July 28, 2026. A separate New York suit by 22NW Fund continues against the company. ## Latest Lifecore Biomedical news 1. 2026-09-28 Mergers [Lifecore Biomedical agrees to $6.28 a share cash sale to Webster Equity Partners](https://aibio.space/news/lifecore-biomedical-agrees-6-28-share-cash-sale-webster-equity/) The deal is valued at up to $663.7 million if performance milestones are met. Contingent value rights could lift total payout to $9.67 per share. 2. 2025-01-07 Financings [Lifecore Biomedical sells unused filling equipment for $17 million, $7 million paid so far](https://aibio.space/news/lifecore-biomedical-sells-unused-filling-equipment-17-million-7/) The contract manufacturer received $7 million at closing and expects the rest in three tranches over 18 months. It says current capacity supports up to $300 million in annual revenue. ## Lifecore Biomedical at a glance - **Ticker**: LFCR - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $17.2 million ### Related companies - [Vanda Pharmaceuticals](https://aibio.space/companies/vanda-pharmaceuticals/) NASDAQ: VNDA - [Minerva Neurosciences](https://aibio.space/companies/minerva-neurosciences/) NASDAQ: NERV - [Pelthos Therapeutics](https://aibio.space/companies/pelthos-therapeutics/) AMEX: PTHS - [Assembly Biosciences](https://aibio.space/companies/assembly-biosciences/) NASDAQ: ASMB - [Biohaven](https://aibio.space/companies/biohaven/) NYSE: BHVN - [Ultragenyx Pharmaceutical](https://aibio.space/companies/ultragenyx-pharmaceutical/) NASDAQ: RARE - [Metagenomi Therapeutics](https://aibio.space/companies/metagenomi-therapeutics/) NASDAQ: MGX - [LENZ Therapeutics](https://aibio.space/companies/lenz-therapeutics/) NASDAQ: LENZ ### Also on NASDAQ - [Co-Diagnostics](https://aibio.space/companies/diagnostics/) CODX - [Tempest Therapeutics](https://aibio.space/companies/tempest-therapeutics/) TPST - [Niki BioSolutions](https://aibio.space/companies/niki-biosolutions/) NIKI - [Nexentis Technologies](https://aibio.space/companies/nexentis-technologies/) NXTS - [Century Therapeutics](https://aibio.space/companies/century-therapeutics/) IPSC - [Royalty Pharma](https://aibio.space/companies/royalty-pharma/) RPRX ## What Lifecore Biomedical does Lifecore Biomedical, Inc., based in Chaska, Minnesota, is a fully integrated contract development and manufacturing organization (CDMO) for complex sterile injectable pharmaceutical and medical device products. It describes itself as a leading U.S. manufacturer of pharmaceutical-grade, non-animal-sourced hyaluronic acid (HA), made with a fermentation-based process it developed in 1981. Lifecore makes HA in bulk form and in filled syringes and vials for customers injectable products, including ophthalmic and orthopedic applications. Its development services include analytical method development, formulation development, sterile filtration, process scale-up, stability studies and production of materials for clinical studies. The company also develops highly viscous non-HA-based sterile injectable products with customers and operates three cGMP facilities. In September 2024 it installed a new fully automated aseptic isolator filler, which it said doubled its revenue-generating capacity to support up to approximately 00 million in annual revenue-generating capacity. Its customer relationships range from 20 years to nearly 40 years. | Product or program | What it is | Stage | |---|---|---| | Hyaluronic acid (HA) | Pharmaceutical-grade, non-animal-sourced HA in bulk and in filled syringes and vials | | | Aseptic filling services | Aseptic filling of complex, highly viscous injectables in syringes, vials and cartridges | | | Non-HA viscous sterile injectables | Highly viscous non-HA-based sterile injectable products developed with customers | | Summarised from the company's [10-K filed Aug 7, 2025](https://www.sec.gov/Archives/edgar/data/1005286/000100528625000108/lfcr-20250525.htm). ## Lifecore Biomedical annual financials | Line | FY ended May 25, 2025 | FY ended May 26, 2024 | |---|---|---| | Research and development | [$8.3 million](https://www.sec.gov/Archives/edgar/data/1005286/000100528625000108/) | [$8.6 million](https://www.sec.gov/Archives/edgar/data/1005286/000100528625000108/) | | Net income (loss) | [-$38.7 million](https://www.sec.gov/Archives/edgar/data/1005286/000100528625000108/) | [$12.0 million](https://www.sec.gov/Archives/edgar/data/1005286/000100528625000108/) | | Cash from operations | [-$206,000](https://www.sec.gov/Archives/edgar/data/1005286/000100528625000108/) | [$257,000](https://www.sec.gov/Archives/edgar/data/1005286/000100528625000108/) | | Cash and equivalents | [$8.3 million](https://www.sec.gov/Archives/edgar/data/1005286/000100528625000148/) | [$8.5 million](https://www.sec.gov/Archives/edgar/data/1005286/000100528625000108/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $17.2 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Lifecore Biomedical Is there a class action against Lifecore Biomedical? Our latest story on this, dated Oct 20, 2026: "Lifecore reports July hearing on securities class action settlement". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/lifecore-reports-july-hearing-securities-class-action-settlement/). Has Lifecore Biomedical settled a lawsuit? Our latest story on this, dated Oct 20, 2026: "Lifecore reports July hearing on securities class action settlement". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/lifecore-reports-july-hearing-securities-class-action-settlement/). What is the ticker symbol of Lifecore Biomedical? Lifecore Biomedical, Inc. trades under the ticker LFCR on NASDAQ. Where is Lifecore Biomedical listed? Lifecore Biomedical, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:LDE. What is the SEC CIK of Lifecore Biomedical? The SEC Central Index Key (CIK) for Lifecore Biomedical, Inc. is 1005286. Its filings are on SEC EDGAR. How many shares does Lifecore Biomedical have outstanding? 37,853,060 shares as of 2026-07-29, per the cover page of its 10-Q filed 2026-08-05. Which country or territory is Lifecore Biomedical listed under? Our directory records Lifecore Biomedical, Inc. under United States. What does Lifecore Biomedical do? Our directory classifies Lifecore Biomedical, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Lifecore Biomedical? The ISIN recorded for Lifecore Biomedical, Inc. is US5147661046. Does aibio.space cover Lifecore Biomedical? aibio.space lists Lifecore Biomedical, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Lifecore Biomedical incorporated? SEC records list its state or country of incorporation as DE. What does Lifecore Biomedical develop? Lifecore Biomedical, Inc., based in Chaska, Minnesota, is a fully integrated contract development and manufacturing organization (CDMO) for complex sterile injectable pharmaceutical and medical device products. It describes itself as a leading U.S. manufacturer of pharmaceutical-grade, non-animal-sourced hyaluronic acid (HA), made with a fermentation-based process it developed in 1981. What is Hyaluronic acid (HA) from Lifecore Biomedical? Hyaluronic acid (HA): Pharmaceutical-grade, non-animal-sourced HA in bulk and in filled syringes and vials What is Aseptic filling services from Lifecore Biomedical? Aseptic filling services: Aseptic filling of complex, highly viscous injectables in syringes, vials and cartridges Is Lifecore Biomedical profitable? Lifecore Biomedical, Inc. reported a net loss of $38.7 million for the fiscal year ended May 25, 2025, and used $206,000 of cash in operations, per its annual report to the SEC. ## Investor discussion: Lifecore Biomedical Members talk about Lifecore Biomedical (LFCR). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Lifecore Biomedical, newest first. Each line links the filing it comes from. 1. 2026-09-28 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1005286/000114036126037767/ef20082009_ex99-1.htm) 2. 2025-08-18 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1005286/000100528625000118/lndc-20250812.htm) 3. 2025-01-17 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1005286/000100528625000028/a2025-01x17form8xkex991.htm) 4. 2025-01-07 Financings Reported a financing. SEC Form 8-K (Items 7.01). [Source](https://www.sec.gov/Archives/edgar/data/1005286/000100528625000014/a2025-01x07form8xkex991.htm) 5. 2025-01-02 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 2.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1005286/000100528625000009/a8kex991earningsrelease25q2.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:LFCR on TradingView](https://www.tradingview.com/symbols/NASDAQ-LFCR/). ## SEC filings and registration - **SEC name**: Lifecore Biomedical, Inc. \De\ - **CIK**: 1005286 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: LFCR (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: May 25 - **Filer category**: Accelerated filer
Smaller reporting company - **Business address**: 3515 LYMAN BOULEVARD, CHASKA, MN, 55318 - **Phone**: 9523684300 - **Shares outstanding**: 37,853,060 as of 2026-07-29 (10-Q filed 2026-08-05) - **Former names**: LANDEC CORP \CA\ ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1005286/000100528626000040/lfcr-20261016.htm) filed 2026-10-20 - [8-K](https://www.sec.gov/Archives/edgar/data/1005286/000100528626000036/lfcr-20260924.htm) filed 2026-09-29 - [8-K](https://www.sec.gov/Archives/edgar/data/1005286/000114036126037767/ef20082009_8k.htm) filed 2026-09-28 - [10-Q](https://www.sec.gov/Archives/edgar/data/1005286/000100528626000033/lfcr-20260630.htm) filed 2026-08-05 - [8-K](https://www.sec.gov/Archives/edgar/data/1005286/000100528626000032/lfcr-20260805.htm) filed 2026-08-05 - [8-K](https://www.sec.gov/Archives/edgar/data/1005286/000100528626000026/lfcr-20260629.htm) filed 2026-07-02 - [8-K](https://www.sec.gov/Archives/edgar/data/1005286/000100528626000023/lfcr-20260604.htm) filed 2026-06-05 - [10-Q](https://www.sec.gov/Archives/edgar/data/1005286/000100528626000020/lfcr-20260331.htm) filed 2026-05-06 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001005286), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Lifecore Biomedical, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker LFCR, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Lifecore Biomedical, Inc. - **Ticker**: LFCR - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US5147661046 - **Other listed symbols**: GETTEX:LDE - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-LFCR/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/lifecore-biomedical/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Lifecore Biomedical (LFCR) news: class action and settlement", 2026-10-31, https://aibio.space/companies/lifecore-biomedical/